Regions of Attraction Estimation for Tumor Immune Dynamical Systems

Tutorial session: Modeling and Treatment of Cancer

 $\mathsf{Kaouther}\ \mathsf{Moussa}^1$, Mirko Fiacchini 2 , Mazen Alamir 2

 1 UPHF, CNRS, UMR 8201 - LAMIH, F-59313 Valenciennes, France ² Univ. Grenoble Alpes, CNRS, Grenoble INP, GIPSA-lab, 38000 Grenoble, France

Cancer growth modeling

- Modeling cancer dynamics using (ODE's, PDE's...)
- **Compartmental modeling** of cancer dynamics
- **Experimental tests** for cancer are highly expensive
- ▸ Modeling cancer dynamics helps to:
	- 1. Analyze the different involved mechanisms
	- 2. Predict the cancer behavior
	- 3. Provide systematic approaches for cancer drug scheduling

Region of attraction (RoA) estimation for cancer models

- \blacktriangleright RoA is the set of all initial conditions for which there exists a control such that the state trajectory is driven to a stable equilibrium
- \blacktriangleright It is highly important in the context of cancer dynamics to find the set of initial health indicators that can be healed

- \triangleright x: The number of tumor cells
- \blacktriangleright y: The density of immune cells

Outline

2 [Probabilistically certified region of attraction of a cancer model](#page-15-0)

3 [Take-away messages & perspectives](#page-50-0)

 \dot{x}_1 =

 $\dot{x}_2 =$

 x_2 : density of immune cells

 x_1 : number of tumor cells

Immune cells x_2 $\left\lceil \frac{1}{2} \right\rceil$ Tumor x₁

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\begin{aligned} \dot{x}_1 = & \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) \\ \dot{x}_2 = \end{aligned}
$$

 x_2 : density of immune cells

 x_1 : number of tumor cells

Immune cells x_2 Tumor x

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\begin{aligned} \dot{x}_1 = & \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) \\ \dot{x}_2 = & \alpha_Y - \delta_Y x_2 \end{aligned}
$$

 x_2 : density of immune cells

 x_1 : number of tumor cells

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\begin{aligned} \dot{x}_1 &= \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2\\ \dot{x}_2 &= \alpha_Y - \delta_Y x_2 \end{aligned}
$$

 x_2 : density of immune cells

 x_1 : number of tumor cells

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\begin{aligned}\n\dot{x}_1 &= \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2 \\
\dot{x}_2 &= \alpha_Y - \delta_Y x_2 + \mu_I x_1 x_2\n\end{aligned}
$$

 x_2 : density of immune cells

 x_1 : number of tumor cells

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\begin{aligned}\n\dot{x}_1 &= \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2 \\
\dot{x}_2 &= \alpha_Y - \delta_Y x_2 + \mu_I x_1 x_2 - \beta_Y x_1^2 x_2\n\end{aligned}
$$

 x_2 : density of immune cells

 x_1 : number of tumor cells

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\begin{aligned}\n\dot{x}_1 &= \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2 \\
\dot{x}_2 &= \alpha_Y - \delta_Y x_2 + \mu_I x_1 x_2 - \beta_Y x_1^2 x_2\n\end{aligned}
$$

 x_2 : density of immune cells

- x_1 : number of tumor cells
- u_1 : cytotoxic agent

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\dot{x}_1 = \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2 - \kappa_X x_1 u_1
$$

$$
\dot{x}_2 = \alpha_Y - \delta_Y x_2 + \mu_I x_1 x_2 - \beta_Y x_1^2 x_2
$$

 x_2 : density of immune cells

 x_1 : number of tumor cells

 u_1 : cytotoxic agent

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\dot{x}_1 = \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2 - \kappa_X x_1 u_1
$$

$$
\dot{x}_2 = \alpha_Y - \delta_Y x_2 + \mu_I x_1 x_2 - \beta_Y x_1^2 x_2
$$

- x_2 : density of immune cells
- u_2 : immune stimulation agent
- x_1 : number of tumor cells
- u_1 : cytotoxic agent

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\dot{x}_1 = \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2 - \kappa_X x_1 u_1
$$

$$
\dot{x}_2 = \alpha_Y - \delta_Y x_2 + \mu_I x_1 x_2 - \beta_Y x_1^2 x_2 + \kappa_Y x_2 u_2
$$

- x_2 : density of immune cells
- u_2 : immune stimulation agent
- x_1 : number of tumor cells
- u_1 : cytotoxic agent

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

$$
\begin{aligned}\n\dot{x}_1 &= \mu_C x_1 \left(1 - \frac{x_1}{x_\infty} \right) - \gamma_X x_1 x_2 - \kappa_X x_1 u_1 \\
\dot{x}_2 &= \alpha_Y - \delta_Y x_2 + \mu_I x_1 x_2 - \beta_Y x_1^2 x_2 + \kappa_Y x_2 u_2 - \eta_Y x_2 u_1\n\end{aligned}
$$

- x_2 : density of immune cells
- u_2 : immune stimulation agent
- x_1 : number of tumor cells
- u_1 : cytotoxic agent

A. d'Onofrio, U. Ledzewicz, H. Schättler, On the Dynamics of Tumor-Immune System Interactions and Combined Chemo- and Immunotherapy, New Challenges for Cancer Systems Biomedicine, Springer, 2012

Outline

[Modeling cancer immune interactions](#page-4-0)

2 [Probabilistically certified region of attraction of a cancer model](#page-15-0)

[Take-away messages & perspectives](#page-50-0)

Robust optimization problem

min $J(\theta)$
 $\theta \in \Theta$ s.t. $\forall p \quad g_c(\theta, p) = 0$ $g_{\mathcal{C}}(\theta, p) \coloneqq \Bigg\{$ 0 if all the constraints are satisfied 1 otherwise

- \blacktriangleright θ is the decision variable
- \blacktriangleright g_c is an indicator function on the constraints violation

Robust optimization problem

$$
\min_{\theta \in \Theta} J(\theta)
$$

s.t. $\forall p \quad g_c(\theta, p) = 0$

$$
g_c(\theta, p) := \left\{ \begin{array}{ll} 0 & \text{if all the constraints} \\ \text{are satisfied} \\ 1 & \text{otherwise} \end{array} \right\}
$$

- \blacktriangleright θ is the decision variable
- \blacktriangleright g_c is an indicator function on the constraints violation
- \blacktriangleright η is the **precision**

Chance-constrained optimization problem

$$
\min_{\theta \in \Theta} J(\theta) \tag{1}
$$
\n
$$
\text{s.t.} \quad \Pr_{\mathcal{P}}\{g_c(\theta, \rho) = 1\} \le \eta
$$

- \triangleright θ is the decision variable
- \blacktriangleright g_c is an indicator function on the constraints violation
- \blacktriangleright η is the **precision**

Chance-constrained optimization problem

$$
\min_{\theta \in \Theta} J(\theta) \tag{1}
$$
\n
$$
\text{s.t.} \quad \Pr_{\mathcal{P}}\{g_c(\theta, \rho) = 1\} \le \eta
$$

Simplified optimization problem

$$
\min_{\theta \in \Theta} J(\theta)
$$
\n
$$
\sum_{i=1}^{N} g_c(\theta, p^{(i)}) \leq \frac{m}{N} \tag{2}
$$

 m is the number of **violations**

- \triangleright θ is the decision variable
- \blacktriangleright g_c is an indicator function on the constraints violation
- \blacktriangleright η is the **precision**

Chance-constrained optimization problem

$$
\min_{\theta \in \Theta} J(\theta) \tag{1}
$$
\n
$$
\text{s.t.} \quad \Pr_{\mathcal{P}}\{g_c(\theta, \rho) = 1\} \le \eta
$$

Simplified optimization problem

$$
\min_{\theta \in \Theta} J(\theta)
$$
\n
$$
\sum_{i=1}^{N} g_c(\theta, p^{(i)}) \le \frac{m}{N} \tag{2}
$$

- m is the number of **violations**
- Choosing N s.t. (1) is satisfied with **confidence** δ

Validation guaranties

- \blacktriangleright $\theta \in \Theta$ is the **decision** variable with cardinality n_{Θ}
- \blacktriangleright m is the number of **violations**

$Theorem$ [$Álamo$, 2015]

Take N satisfying

$$
N \geq \frac{1}{\eta} \left(m + \ln \left(\frac{n_{\Theta}}{\delta} \right) + \left(2m \ln \left(\frac{n_{\Theta}}{\delta} \right) \right)^{\frac{1}{2}} \right)
$$

then any solution of [\(2\)](#page-16-1) satisfies $\Pr_{\mathcal{P}}\{g_c(\theta, p) = 1\} \leq \eta$ with a probability $\geq 1 - \delta$

 $\blacktriangleright \{p^{(j)}\}_{j=1}^N$ are i.i.d following P \triangleright $\delta \in (0,1)$ is the **confidence**

Validation guaranties

- \blacktriangleright $\theta \in \Theta$ is the **decision** variable with cardinality n_{Θ}
- \blacktriangleright m is the number of **violations**

 $\blacktriangleright \{p^{(j)}\}_{j=1}^N$ are i.i.d following P \triangleright $\delta \in (0,1)$ is the **confidence**

$\overline{\text{Theorem}}$ $\overline{\text{A}}$ *Alamo*, 2015 $\overline{\text{B}}$

Take N satisfying

$$
N \geq \frac{1}{\eta} \left(m + \ln \left(\frac{n_{\Theta}}{\delta} \right) + \left(2m \ln \left(\frac{n_{\Theta}}{\delta} \right) \right)^{\frac{1}{2}} \right)
$$

then any solution of [\(2\)](#page-16-1) satisfies $\Pr_{\mathcal{P}}\{g_c(\theta, p) = 1\} \leq \eta$ with a probability $\geq 1 - \delta$

for $m = 1$ and $\delta = 0.001$

Pharmacokinetics/ Pharmacodynamics

$$
\begin{aligned} \dot{x}_1 &= \mu_C \left(1 - \frac{x_1}{x_\infty} \right) x_1 - \gamma_X x_1 x_2 - \kappa_X \left(\frac{x_4^{\gamma_C}}{x_4^{\gamma_C} + C_{50c}^{\gamma_C}} \right) x_1 \\ \dot{x}_2 &= \mu_I \left(1 - \beta x_1 \right) x_1 x_2 + \alpha_Y - \delta_Y x_2 - \eta_Y x_2 x_3 + \kappa_Y \left(\frac{x_5^{\gamma_i}}{x_5^{\gamma_i} + C_{50i}^{\gamma_i}} \right) x_2 \\ \dot{x}_3 &= - \left(k_1 + k_2 \right) x_3 + s_1 \frac{u_1}{V_1} \\ \dot{x}_4 &= k_{12} \frac{V_1}{V_2} x_3 - k_2 x_4 \\ \dot{x}_5 &= -c_i x_5 + s_2 u_2 \end{aligned}
$$

Treatment protocol & decision variable

 $\theta = [\nu_C, \sigma_C, d_C, \sigma_I, d_I]$

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x \in \mathbb{X}, \quad u \in \mathbb{U}, \quad x(T) \in \Omega
$$

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x \in \mathbb{X}, \quad u \in \mathbb{U}, \quad x(T) \in \Omega
$$

 \blacktriangleright Uncertainties: x_0 and p

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

 $x \in \mathbb{X}, \quad u \in \mathbb{U}, \quad x(\mathcal{T}) \in \Omega$

- \blacktriangleright Uncertainties: x_0 and p
- \triangleright Ω: certified target set

$$
\dot{x}(t)=F(x(t),u(t),p),x(0)=x_0
$$

 $x \in \mathbb{X}, \quad u \in \mathbb{U}, \quad x(\mathcal{T}) \in \Omega$

- \blacktriangleright Uncertainties: x_0 and p
- \triangleright Ω: certified target set
- \blacktriangleright θ defines the drug protocol u

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

 $x \in \mathbb{X}, \quad u \in \mathbb{U}, \quad x(\mathcal{T}) \in \Omega$

- \blacktriangleright Uncertainties: x_0 and p
- \triangleright Ω: certified target set
- \blacktriangleright θ defines the **drug protocol** u
- \blacktriangleright Consider N_c therapeutic cycles

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x\in\mathbb{X},\quad u\in\mathbb{U},\quad x(\mathcal{T})\in\Omega
$$

- \blacktriangleright Uncertainties: x_0 and p
- \triangleright Ω: certified target set
- \blacktriangleright θ defines the **drug protocol** u
- \blacktriangleright Consider N_c therapeutic cycles

▶ $p \sim \mathcal{N}(p_{nom}, 0.01)$ truncated in $[0.9p_{nom}, 1.1p_{nom}]$

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x\in\mathbb{X},\quad u\in\mathbb{U},\quad x(\mathcal{T})\in\Omega
$$

- \blacktriangleright Uncertainties: x_0 and p
- \triangleright Ω: certified target set
- \blacktriangleright θ defines the **drug protocol** u
- \blacktriangleright Consider N_c therapeutic cycles

▶ $p \sim \mathcal{N}(p_{nom}, 0.01)$ truncated in $[0.9p_{nom}, 1.1p_{nom}]$

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x\in\mathbb{X},\quad u\in\mathbb{U},\quad x(\mathcal{T})\in\Omega
$$

- \blacktriangleright Uncertainties: x_0 and p
- \blacktriangleright Ω: certified target set
- \blacktriangleright θ defines the **drug protocol** u
- \blacktriangleright Consider N_c therapeutic cycles

▶ $p \sim \mathcal{N}(p_{nom}, 0.01)$ truncated in $[0.9p_{nom}, 1.1p_{nom}]$

 Ω_0 is the certified safe region

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x\in\mathbb{X},\quad u\in\mathbb{U},\quad x(\mathcal{T})\in\Omega
$$

- \blacktriangleright Uncertainties: x_0 and p
- \triangleright Ω: certified target set
- \blacktriangleright θ defines the **drug protocol** u
- \blacktriangleright Consider N_c therapeutic cycles

▶ $p \sim \mathcal{N}(p_{nom}, 0.01)$ truncated in $[0.9p_{nom}, 1.1p_{nom}]$

- Ω_0 is the certified safe region
- ► We derive a sequence $\{\Omega_k\}_{k=1}^{N_C}$ $k=1$

 \triangleright x₀ ∼ U (Ω_k)

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x\in\mathbb{X},\quad u\in\mathbb{U},\quad x(\mathcal{T})\in\Omega
$$

- \blacktriangleright Uncertainties: x_0 and p
- \blacktriangleright Ω: certified target set
- \blacktriangleright θ defines the **drug protocol** u
- \blacktriangleright Consider N_c therapeutic cycles

▶ $p \sim \mathcal{N}(p_{nom}, 0.01)$ truncated in $[0.9p_{nom}, 1.1p_{nom}]$

- Ω_0 is the certified safe region
- ► We derive a sequence $\{\Omega_k\}_{k=1}^{N_C}$ $k=1$

$$
\blacktriangleright x_0 \sim \mathcal{U}\left(\Omega_k\right)
$$

$$
\blacktriangleright \ \theta_{\Omega_{k+1} \to \bigcup_{j=0}^k \Omega_j}
$$

$$
\dot{x}(t) = F(x(t), u(t), p), x(0) = x_0
$$

$$
x\in\mathbb{X},\quad u\in\mathbb{U},\quad x(\mathcal{T})\in\Omega
$$

- \blacktriangleright Uncertainties: x_0 and p
- \triangleright Ω: certified target set
- \blacktriangleright θ defines the **drug protocol** u
- \blacktriangleright Consider N_c therapeutic cycles

▶ $p \sim \mathcal{N}(p_{nom}, 0.01)$ truncated in $[0.9p_{nom}, 1.1p_{nom}]$

- Ω_0 is the certified safe region
- ► We derive a sequence $\{\Omega_k\}_{k=1}^{N_C}$ $k=1$

$$
\blacktriangleright x_0 \sim \mathcal{U}\left(\Omega_k\right)
$$

$$
\triangleright \theta_{\Omega_{k+1} \to \bigcup_{j=0}^{k} \Omega_j}
$$

$$
\triangleright \Omega_C = \bigcup_{j=0}^{N_C} \Omega_j
$$

Validation of the certified target set Ω_0 without control

▶ 5000 Monte-Carlo tests were performed

Problem setup

Constraints:

 $x_2(t) \geq c$, with $c \in \mathbb{R}_+$ $0 \le u_1(t) \le 1$ $0 \le u_2(t) \le 1$

Problem setup

Constraints:

$$
x_2(t) \ge c, \text{ with } c \in \mathbb{R}_+
$$

$$
0 \le u_1(t) \le 1
$$

$$
0 \le u_2(t) \le 1
$$

Failure indicator:

$$
g_c := \Bigg\{
$$

0 if $x_2(t|x_0, p, \theta) \geq c \quad \forall t$ and $x(T|x_0, p, \theta) \in \Omega$ 1 otherwise

Problem setup

Constraints:

$$
x_2(t) \ge c, \text{ with } c \in \mathbb{R}_+
$$

$$
0 \le u_1(t) \le 1
$$

$$
0 \le u_2(t) \le 1
$$

Failure indicator:

$$
g_c := \Bigg\{
$$

0 if $x_2(t|x_0, p, \theta) \geq c \quad \forall t$ and $x(T|x_0, p, \theta) \in \Omega$ 1 otherwise

- ▸ The number of control protocols is $n_{\Theta} = 300$
- Accepted failures $m = 1$
- ► Precision parameter $n = 10^{-2}$
- ► Confidence parameter $\delta = 10^{-3}$
- Number of scenarios $N > 1863$

$$
N_{sim} = N \cdot n_{\Theta} = 558900
$$

- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

```
\begin{cases} \begin{bmatrix} \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} \\ \frac{1}{2} & \frac{1}{2} \end{bmatrix} \end{cases}\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
        d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1 }.
```
- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

```
\int\{\begin{array}{c}\n\end{array}\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
     d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1
```


- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

```
\int\{\begin{array}{c}\n\end{array}\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
     d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1
```


- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

```
\int\{\begin{array}{c}\n\end{array}\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
     d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1
```


 $\theta = [\nu_C, \sigma_C, d_C, \sigma_I, d_I]$

- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1

x¹

```
\int\{\begin{array}{c}\n\end{array}\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
     d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1
```


 -10^{3}

 $x_2 = c$ $\Omega_{u}^{\rho_{nom}}$ ∎Ωe Ω

Cycle 1 (Ω1)

 $0\frac{L}{0}$ 0.2 0.4 0.6 0.8 1 1.2 1.4

 $\ddot{\times}$

 $\theta = [\nu_C, \sigma_C, d_C, \sigma_I, d_I]$

- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

```
\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1
```


$$
\begin{aligned}\n\theta &= (0.2, 0.5, 0, 0.64, 0.25) \\
\theta &= (0.2, 0.5, 0.67, 0.64, 1) \\
\Omega_2 \rightarrow \Omega_1 \cup \Omega_0\n\end{aligned}
$$

 $\theta = [\nu_C, \sigma_C, d_C, \sigma_I, d_I]$

- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

```
\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1
```


$$
\begin{array}{c}\n\theta = (0.2, 0.5, 0, 0.64, 0.25) \\
\theta = (0.2, 0.5, 0.67, 0.64, 1) \\
\Omega_2 \rightarrow \Omega_1 \cup \Omega_0\n\end{array}
$$

 $\theta = [\nu_C, \sigma_C, d_C, \sigma_I, d_I]$

- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

```
\sigma<sub>I</sub> \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},\sigma_C = 0.5, \nu_C = 0.2,
d_I \in \{0, 0.25, 0.5, 0.75, 1\},d_C \in \{0, 0.11, 0.22, 0.33,0.44, 0.56, 0.67, 0.78, 0.89, 1
```


$$
\begin{gathered}\\ \theta\\ \Omega_1\rightarrow\Omega_0\\ \theta\\ \Omega_2\rightarrow\Omega_1\cup\Omega_0\end{gathered}(0.2,0.5,0.67,0.64,1)
$$

 $\theta = [\nu_C, \sigma_C, d_C, \sigma_I, d_I]$

- \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy
- \blacktriangleright σ _I: duration of immunotherapy

Cycle 2 (2)

Cycle 3 (Ω3)

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1

 x_1

$$
\sigma_l \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},
$$

\n
$$
\sigma_C = 0.5, \quad \nu_C = 0.2,
$$

\n
$$
d_l \in \{0, 0.25, 0.5, 0.75, 1\},
$$

\n
$$
d_C \in \{0, 0.11, 0.22, 0.33,
$$

\n0.44, 0.56, 0.67, 0.78, 0.89, 1\}.

 $x_2 = c$ $\Omega_{u}^{\rho_{nom}}$ Ω_{P} Ω

Cycle 1 (Ω1)

 $0\frac{L}{0}$ 0.2 0.4 0.6 0.8 1 1.2 1.4

 $\ddot{\times}$

 -10^{3}

 $\theta = [\nu_C, \sigma_C, d_C, \sigma_I, d_I]$

 \blacktriangleright d_C , d_I : concentration of chemoand immunotherapy

$$
\blacktriangleright
$$
 σ_I : duration of immunotherapy

Cycle 2 (2)

Cycle 3 (Ω3)

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1

 x_1

$$
\sigma_l \in \{0, 0.16, 0.32, 0.48, 0.64, 0.8\},
$$

\n
$$
\sigma_C = 0.5, \quad \nu_C = 0.2,
$$

\n
$$
d_l \in \{0, 0.25, 0.5, 0.75, 1\},
$$

\n
$$
d_C \in \{0, 0.11, 0.22, 0.33,
$$

\n0.44, 0.56, 0.67, 0.78, 0.89, 1\}.

 θ = (0.2, 0.5, 0, 0.64, 0.25) $\stackrel{\theta}{\Omega}_2 \rightarrow \stackrel{\theta}{\Omega}_1 \cup \stackrel{\theta}{\Omega}_0$ $=(0.2, 0.5, 0.67, 0.64, 1)$ θ = (0.2, 0.5, 0.56, 0.8, 0.5)
 $\Omega_3 \rightarrow \Omega_2 \cup \Omega_1 \cup \Omega_0$

 $\Omega_C = \Omega_0 \cup \Omega_1 \cup \Omega_2 \cup \Omega_3$

 -10^{3}

 \int $\{$ $\begin{array}{c}\n\end{array}$

 $x_2 = c$ $\Omega_{u}^{\rho_{nom}}$ Ω_{P} Ω

Cycle 1 (Ω1)

 $0\frac{L}{0}$ 0.2 0.4 0.6 0.8 1 1.2 1.4

 $\ddot{\times}$

Validation of the estimation of Ω_c

▶ 5000 Monte-Carlo tests were performed

Outline

[Probabilistically certified region of attraction of a cancer model](#page-15-0)

3 [Take-away messages & perspectives](#page-50-0)

Take-away messages & perspectives

▶ A framework of **probabilistic certification** for **RoA**

- $+$ Avoid conservatism
- $+$ Provide the **certified control law**
- Might be computationally expensive
- \rightarrow use Matlab Coder or parallel computing
- \rightarrow use iterative algorithms to avoid enumeration

Future perspectives:

Take-away messages & perspectives

▶ A framework of **probabilistic certification** for **RoA**

- $+$ Avoid conservatism
- $+$ Provide the **certified control law**
- Might be computationally expensive
- \rightarrow use Matlab Coder or parallel computing
- \rightarrow use iterative algorithms to avoid enumeration

Future perspectives:

Take-away messages & perspectives

▶ A framework of **probabilistic certification** for **RoA**

- $+$ Avoid conservatism
- $+$ Provide the **certified control law**
- Might be computationally expensive
- \rightarrow use Matlab Coder or parallel computing
- \rightarrow use **iterative** algorithms to avoid enumeration

Future perspectives:

- Application of the probabilistic framework to other models
- Other types of **set generators** in the RoA probabilistic certification
- Derive formal **bounds** on the final convergence probability

Thank you for your attention!